Literature DB >> 26421371

Psoriasis and the Risk of Depression in the US Population: National Health and Nutrition Examination Survey 2009-2012.

Brandon E Cohen1, Kathryn J Martires1, Roger S Ho1.   

Abstract

IMPORTANCE: Psoriasis is a risk factor for depression. Depression may also trigger or exacerbate psoriasis. The relationship between psoriasis and depression, however, remains to be fully explored.
OBJECTIVE: To investigate the association between psoriasis and major depression in the US population. DESIGN, SETTING, AND PARTICIPANTS: Population-based study using participants in the National Health and Nutrition Examination Survey from 2009 through 2012. MAIN OUTCOMES AND MEASURES: Diagnosis of major depression based on the Patient Health Questionnaire-9.
RESULTS: We identified 351 (2.8%) cases of psoriasis and 968 (7.8%) cases of major depression among 12,382 US citizens included in our study. Fifty-eight (16.5%) patients with psoriasis met criteria for a diagnosis of major depression. The mean (SD) Patient Health Questionnaire-9 score was significantly higher among patients with a history of psoriasis than those without psoriasis (4.54 [5.7] vs 3.22 [4.3], P < .001). Psoriasis was significantly associated with major depression, even after adjustment for sex, age, race, body mass index, physical activity, smoking history, alcohol use, history of myocardial infarction (MI), history of stroke, and history of diabetes mellitus (OR, 2.09 [95% CI, 1.41-3.11], P < .001). Interaction term analyses involving patients with a history of both psoriasis and a cardiovascular event, specifically MI or stroke, did not reveal a synergistically increased risk of major depression (psoriasis and MI: OR, 1.09 [95% CI, 0.28-3.60], P = .91; psoriasis and stroke: OR, 0.67 [95% CI, 0.12-3.66], P = .63). In adjusted multivariable models, the risk of major depression was not significantly different between patients with limited vs extensive psoriasis (OR, 0.66 [95% CI, 0.18-2.44], P = .53). CONCLUSIONS AND RELEVANCE: Self-reported history of psoriasis was independently associated with major depression as assessed by a validated screening tool, even when controlling for comorbidities. History of cardiovascular event did not modify the risk of major depression for patients with psoriasis. The severity of psoriasis was unrelated to the risk of major depression. Therefore, all patients with psoriasis, regardless of severity, may be at risk for major depression.

Entities:  

Mesh:

Year:  2016        PMID: 26421371     DOI: 10.1001/jamadermatol.2015.3605

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN: 2168-6068            Impact factor:   10.282


  32 in total

1.  Association of Skin Psoriasis and Somatic Comorbidity With the Development of Psychiatric Illness in a Nationwide Swedish Study.

Authors:  Kirk Geale; Martin Henriksson; Jussi Jokinen; Marcus Schmitt-Egenolf
Journal:  JAMA Dermatol       Date:  2020-07-01       Impact factor: 10.282

2.  Depression and anxiety among patients with psoriasis: A correlation with quality of life and associated factors.

Authors:  Raishan S Bakar; Sharifah Z S Jaapar; Afiq F Azmi; Yeoh C Aun
Journal:  J Taibah Univ Med Sci       Date:  2021-03-16

Review 3.  Roles of Infection in Psoriasis.

Authors:  Shihui Zhou; Zhirong Yao
Journal:  Int J Mol Sci       Date:  2022-06-23       Impact factor: 6.208

4.  Safety of Ixekizumab in Adult Patients with Moderate-to-Severe Psoriasis: Data from 17 Clinical Trials with Over 18,000 Patient-Years of Exposure.

Authors:  Christopher E M Griffiths; Melinda Gooderham; Jean-Frederic Colombel; Tadashi Terui; Ana P Accioly; Gaia Gallo; Danting Zhu; Andrew Blauvelt
Journal:  Dermatol Ther (Heidelb)       Date:  2022-05-27

5.  Psychosocial aspects of obesity in adults with psoriasis: A systematic review.

Authors:  N T Pavlova; K Kioskli; C Smith; F Picariello; L Rayner; R Moss-Morris
Journal:  Skin Health Dis       Date:  2021-05-03

6.  Psychological Distress, Alexithymia and Alcohol Misuse in Patients with Psoriasis: A Cross-Sectional Study.

Authors:  Ourania Founta; Karoline Adamzik; Anne-Marie Tobin; Brian Kirby; David Hevey
Journal:  J Clin Psychol Med Settings       Date:  2019-06

7.  The Challenge of Variable Costs in Decisions Based on Cost-Effectiveness Evidence: A Case Study for Brodalumab.

Authors:  Diana Brixner; Gary Oderda; Joseph Biskupiak; Douglas S Burgoyne; Steven G Avey; Steven R Feldman
Journal:  Am Health Drug Benefits       Date:  2019-02

8.  Serum 5-Hydroxytryptamine is Related to Psoriasis Severity in Patients with Comorbid Anxiety or Depression.

Authors:  Minxue Shen; Duling Cao; Yi Xiao; Yehong Kuang; Danrong Jing; Yajia Li; Panpan Liu; Xiang Chen; Wu Zhu
Journal:  Acta Derm Venereol       Date:  2021-08-16       Impact factor: 3.875

Review 9.  New Frontiers in Psoriatic Disease Research, Part II: Comorbidities and Targeted Therapies.

Authors:  Di Yan; Andrew Blauvelt; Amit K Dey; Rachel S Golpanian; Samuel T Hwang; Nehal N Mehta; Bridget Myers; Zhen-Rui Shi; Gil Yosipovitch; Stacie Bell; Wilson Liao
Journal:  J Invest Dermatol       Date:  2021-04-19       Impact factor: 7.590

10.  Sex and Age Influence the Associated Risk of Depression in Patients with Psoriasis: A Retrospective Population Study Based on Diagnosis and Drug-Use.

Authors:  Albert Duvetorp; Ulrich Mrowietz; Mats Nilsson; Oliver Seifert
Journal:  Dermatology       Date:  2020-09-14       Impact factor: 5.366

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.